The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL-17A and IL-17AF) and are capable of inhibiting IL-17A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.本發明係關於特異性結合於促炎性細胞激素IL-17A之抗體及包含其抗原結合部分的蛋白質。更特定言之，本發明係關於作為IL-17A拮抗劑(抑制IL-17A及IL-17AF的活性)且能夠在活體外分析中抑制IL-17A誘發之細胞激素產生且在抗原誘發之關節炎之活體內模型中具有抑制作用的特異性抗體及蛋白質。本發明進一步關於使用該等抗體及蛋白質治療可藉由抑制IL-17A或IL17AF介導之活性而得到治療之病理性病症的組合物及方法，該等病理性病症為諸如類風濕性關節炎、牛皮癬、全身性紅斑狼瘡症(SLE)、狼瘡腎炎、慢性阻塞性肺病、哮喘或囊腫性纖維化或其他自體免疫及發炎病症。
